Oxygen Containing Reactant Patents (Class 530/406)
-
Patent number: 7138504Abstract: The invention teaches derivatives of mycophenolic alcohol and methods of preparing immunogens and other conjugates useful in immunoassays for quantitatively measuring concentrations of mycophenolic acid (MPA) and/or active metabolites of MPA in patient specimens. Antibodies produced from the disclosed immunogens capable of binding to MPA with cross-reactivity of no more than 5% with inactive metabolites and commonly co-prescribed drugs. Further, immunoassays for measuring the concentration of MPA using such antibodies are taught.Type: GrantFiled: August 11, 2005Date of Patent: November 21, 2006Assignee: Microgenics CorporationInventors: Vani B. Bodepudi, Amy P. Tsai, Weixing Luo, Rueyming Loor
-
Patent number: 7129327Abstract: Protein and polypeptid derivatives and their salts are claimed characterized in that a protein or polypeptide is conjugated via an intermediate grouping containing at least one radical of the formula —C(R)?N— (or —N?C(R)—) or —CH(R)—NH— (or —NH—CH(R)—), wherein R is hydrogen or a hydrocarbon residue which may be substituted, with the same or a different protein or polypeptide, with a reporter group or a cytotoxic agent as well as a process for their preparation and the novel intermediates therefor.Type: GrantFiled: September 30, 2003Date of Patent: October 31, 2006Assignee: Amylin Pharmaceuticals, Inc.Inventors: Robin Ewart Offord, Keith Rose
-
Patent number: 7109309Abstract: It is intended to provide an antibody specific to HbA1c, antibody-producing cells capable of supplying the antibody in a stable state in the future, and a method of constructing the antibody-producing cells without any probability factors, and a method which comprises fusing mouse spleen cells, which have been sensitized with an immunogen composed of a compound containing the following structural formula (I) and a binding protein, with a myeloma-origin cell line, obtaining monoclonal antibody-producing cells by cloning, and then purifying and acquiring the monoclonal antibody produced by these cells into the culture supernatantType: GrantFiled: July 13, 2001Date of Patent: September 19, 2006Assignee: Matsushita Electric Industrial Co., Ltd.Inventors: Nobuyuki Shigetoh, Hiroshi Nakayama, Keiko Yugawa, Fumihisa Kitawaki
-
Patent number: 7052686Abstract: Interleukin-10 (IL-10) conjugated via a linker to one or more polyethylene glycol (PEG) molecules at a single amino acid residue of the IL-10, and a method for preparing the same, are provided. The method produces a stable mono-pegylated IL-10, which retains IL-10 activity, where pegylation is selective for the N-terminus on one subunit of IL-10 with little or no formation of monomeric IL-10. The method also provides a substantially homogenous population of mono-PEG-IL-10.Type: GrantFiled: September 28, 2001Date of Patent: May 30, 2006Assignee: Schering CorporationInventors: Seoju Lee, David C. Wylie, Susan V. Cannon-Carlson
-
Patent number: 7052863Abstract: An alizarin-based chromogenic substrate, a composition containing the substrate, and its use to detect the presence of an enzymatic activity are disclosed. The substrate is particularly applicable in the field of biological diagnosis.Type: GrantFiled: December 11, 2000Date of Patent: May 30, 2006Assignee: Biomerieux S. A.Inventors: Lyle Armstrong, Arthur James
-
Patent number: 7011968Abstract: The invention relates to a synthetic, biologically active molecule for fixing an active ingredient to the virus protein 1 (VP1) of the polyoma virus. According to the invention, an amino acid sequence A1 which is derived from the C-terminal end of virus protein 2 (VP2) or 3 (VP3) of the polyoma virus is bonded to an active ingredient at one of its ends.Type: GrantFiled: April 3, 2000Date of Patent: March 14, 2006Assignee: november Aktiengesellschaft Gesellschaft fur Molekulare MedizinInventors: Jurgen Walter, Christian Reiser, Wolf Bertling
-
Patent number: 6967240Abstract: The present invention relates to a protienaceous compound or functionally active derivative or part thereof having a binding site for a group represented by formula (I) which is part of a group of toxins derived from various cyanobacteria, to a method for its production, to diagnostic kits and to an affinty matrix (e.g. for use in immunoaffinity columns, online detection and purifications devices) containing the proteinaceous compound as well as to methods for substantially decreasing the amount of a compound containing the group represented by formula (I) in fluids or for concentrating compounds, e.g. toxins, containing the group represented by formula (I) from fluids such as crude water samples, extracts of algae or other tissue samples, e.g. to determine toxin concentrations.Type: GrantFiled: September 6, 2000Date of Patent: November 22, 2005Assignees: The Regent of the University of California, New Zealand Agricultural Research Institute LimitedInventors: Daniel R. Dietrich, Werner Fischer, A. Richard Chamberlin, James B. Aggen, Ian Garthwaite, Christopher O. Miles, Kathryn M. Ross, Neale R. Towers
-
Patent number: 6956027Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel chemically modified G-CSF compositions and related methods of preparation.Type: GrantFiled: October 4, 2002Date of Patent: October 18, 2005Assignee: Amgen Inc.Inventor: Olaf B. Kinstler
-
Patent number: 6932971Abstract: The present invention provides compositions comprising a conjugate of a hapten with a carrier in an ordered and repetitive array, and methods of making such compositions. The conjugates and compositions of the invention may comprise a variety of haptens, including hormones, toxins and drugs, especially drugs of addiction such as nicotine. Compositions and conjugates of the invention are useful for inducing immune responses against haptens, which can use useful in a variety of therapeutic, prophylactic and diagnostic regimens. In certain embodiments, immune responses generated using the conjugates, compositions and methods of the present invention are useful to prevent or treat addiction to drugs of abuse and the resultant diseases associated with drug addiction.Type: GrantFiled: July 18, 2003Date of Patent: August 23, 2005Assignee: Cytos Biotechnology AGInventors: Martin F. Bachmann, Patrik Maurer
-
Patent number: 6913936Abstract: A novel compound comprising an immunologically invisible polyethylene glycol copolymer is used to carry one or more immunologically reactive substances. The novel compounds may be used as part of kits for immunological assays.Type: GrantFiled: October 17, 2001Date of Patent: July 5, 2005Assignee: University of Medicine and Dentistry of New JerseyInventors: Bo Qiu, Guobao Zhang, Stanley Stein, Leonard H Sigal, Michael Brunner, Michael Katz
-
Patent number: 6869932Abstract: A method is described for the site-specific preparation of hGRF-PEG conjugates containing one or more PEG units (per mole of hGRF) covalently bound to Lys12 and/or Lys21 and/or N?, characterized in that the conjugation reaction between the hGRF peptide and activated PEG is carried out in solution and the desired hGRF-PEG conjugate can be purified by chromatography. The conjugates prepared by this method, as well as their use in the treatment, prevention or diagnosis of growth hormone deficiency, are also an object of the present invention.Type: GrantFiled: November 20, 2002Date of Patent: March 22, 2005Assignee: Applied Research Systems ARS Holding N.V.Inventors: Francesco Maria Veronese, Paolo Caliceti, Oddone Schiavon
-
Patent number: 6858211Abstract: This invention relates to conjugates of the O-specific polysaccharide of E. coli O157 with a carrier, and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in mammals, including responses which provide protection against, or reduce the severity of, bacterial infections. More particularly it relates to the use of polysaccharides containing the tetrasaccharide repeat unit: (?3)-?-D-GalpNAc-(1?2)-?-D-PerpNAc-(1?3)-?-L-Fucp-(1?4)-?-D-Glcp-(1?), and conjugates thereof, to induce serum antibodies having bactericidal (killing) activity against hemolytic-uremic syndrome (HUS) causing E. coli, in particular E. coli O157. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies which have bactericidal or bacteriostatic activity against against E. coli, in particular E. coli O157, and are useful to prevent and/or treat illnesses caused by E. coli O157.Type: GrantFiled: July 20, 1998Date of Patent: February 22, 2005Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Shousun Chen Szu, John B. Robbins, Yvonne Ageyman Konadu, Edward Konadu
-
Patent number: 6824997Abstract: A process is disclosed for obtaining a C-polysaccharide cell wall antigen containing not more than about 10% protein from Streptococcus pneumoniae bacteria. The antigen thus obtained is conjugated to a spacer molecule, and the free end of the latter is then conjugated to a chromatographic affinity column. The column is then utilized to purify raw antibodies to S. pneumonia bacteria, thereby producing antigen-specific antibodies. A portion of such antibodies is conjugated to a labeling agent which displays a visible color change upon reaction of the antibodies with their antigenic binding partner and embedded in a first zone of an immunochromatographic assay device. Another portion of such antibodies is bound to the reaction zone of the device which has a view window.Type: GrantFiled: September 16, 1999Date of Patent: November 30, 2004Assignee: BINAX, Inc.Inventors: Norman James Moore, Mary Kathleen Fent, Vladimir Andrei Koulchin, Elena Valentin Molokova
-
Patent number: 6814971Abstract: The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal.Type: GrantFiled: March 13, 2003Date of Patent: November 9, 2004Assignee: Pfizer Inc.Inventors: David S. Roberts, Leroy A. Swearingin, Don A. Dearwester
-
Patent number: 6809177Abstract: The invention relates to a process for the conversion of echinocandin class of peptides to their C4-homotyrosine monodeoxy analogues, particularly mulundocandin to deoxymulundocandin, which consists of a single step selective reduction of C4-htyr (homotyrosine) hydroxyl group of echinocandins to their monodeoxy analogues under neutral conditions without prior protection/deprotection of the equally facile C5-Orn (ornithine) hydroxyl group and purification of the monodeoxy compound from the crude reaction mixture.Type: GrantFiled: March 29, 2001Date of Patent: October 26, 2004Assignee: Aventis Pharma Deutschland GmbH.Inventors: Triptikumar Mukhopadhyay, Kenia Jayvanti, Erra Koteswara Satya Vijaya Kumar
-
Patent number: 6756041Abstract: A process for preparing a protein-polysaccharide conjugate includes reacting a protein with a polysaccharide to produce a mixture including a protein-polysaccharide conjugate and free protein. At least one unreacted reagent or low molecular weight component is removed from this mixture, without removing all of the free protein, to provide a purified mixture that contains the protein-polysaccharide conjugate and free protein. This purified mixture can be used as a conjugate vaccine, immunogen, or immunological reagent. Keeping the free protein in the purified mixture with the conjugate saves time and money in the conjugate production process. In another aspect of the invention, the purified mixture of the protein-polysaccharide conjugate and free protein is reacted with a hapten to produce a conjugate mixture including a hapten-protein conjugate and a hapten-protein-polysaccharide conjugate.Type: GrantFiled: December 13, 2000Date of Patent: June 29, 2004Assignee: Henry M. Jackson Foundation for the Advancement of Military MedicineInventors: Andrew Lees, James Mond
-
Publication number: 20040121400Abstract: The invention provides a hapten, an immunogen comprising the hapten coupled to an antigenicity-conferring carrier material, a conjugate comprising the hapten coupled to a labelling agent, as well as, antibodies raised against the aforementioned immunogen and capable of binding with MDMA.Type: ApplicationFiled: December 20, 2002Publication date: June 24, 2004Inventors: Robert Ivan McConnell, Elouard Benchikh, Stephen Peter Fitzgerald, John Victor Lamont
-
Patent number: 6749642Abstract: The present invention provides regenerated collagen fibers which have light color and excellent touch in wet conditions and which can be formed into desirable shape with the shape being maintained properly. The present invention also provides regenerated collagen fibers whose foul odor generated in thermal treatment can be inhibited. The present invention relates to regenerated collagen fibers obtained by treating collagen with a monofunctional epoxy compound and an aluminum salt. The present invention also relates to a process for preparing regenerated collagen fibers which comprises treating collagen with a monofunctional epoxy compound, and then treating the same in such a way that 2 to 40% by weight of an aluminum salt converted to an aluminum oxide (Al2O3) basis is contained to said collagen.Type: GrantFiled: December 17, 2001Date of Patent: June 15, 2004Assignees: Kaneka Corporation, Hokuyo Co., Ltd.Inventors: Masahiro Ueda, Yoshihiro Makihara, Takashi Ueda, Kunihiko Matsumura
-
Patent number: 6673347Abstract: Protein and polypeptide derivatives and their salts are claimed characterized in that a protein or polypeptide is conjugated via an intermediate grouping containing at least one radical of the formula —C(R)═N— (or —N═C(R)—) or —CH(R)—NH— (or —NH—CH(R)—), wherein R is hydrogen or a hydrocarbon residue which may be substituted, with the same or a different protein or polypeptide, with a reporter group or a cytotoxic agent as well as a process for their preparation and the novel intermediates therefor.Type: GrantFiled: May 12, 1994Date of Patent: January 6, 2004Assignee: Gryphon TherapeuticsInventors: Robin Ewart Offord, Keith Rose
-
Patent number: 6663869Abstract: A homogeneous polyoxime composition is provided, in which the polyoxime molecules present comprise a first organic baseplate molecule, which is a polypeptide, wherein the baseplate molecule is linked to at least two second organic molecules, which may be the same or different from one another. In the compositions, the linkages between the baseplate and said organic molecules are oxime linkages formed by reaction of an orthogonal reactive group on each the organic molecules with a complementary orthogonal reactive group on the baseplate.Type: GrantFiled: August 4, 2000Date of Patent: December 16, 2003Assignee: Gryphon Therapeutics, Inc.Inventors: Keith Rose, Robin E. Offord
-
Publication number: 20030220264Abstract: An process for the reversible modification of membrane interaction of a compound is described. Modification of membrane interaction can be used to facilitate delivery of molecules to cells in vitro and in vivo. The described modifiers, which are used to reversibly inactivate the membrane active compounds, can also be utilized as cross-linkers or to reverse the charge of a molecule.Type: ApplicationFiled: May 23, 2003Publication date: November 27, 2003Inventors: David B. Rozema, Darren Wakefield, Jon A. Wolff, Kirk Ekena, James E. Hagstrom
-
Patent number: 6632437Abstract: The present invention relates to a polysaccharide-protein conjugate. The invention also relates to a method of using the conjugate to prevent systemic infections. The invention further relates to a pharmaceutical composition. The invention also relates to a method of producing a polysaccharide-protein conjugate.Type: GrantFiled: November 15, 1993Date of Patent: October 14, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Rachel Schneerson, John B. Robbins, J. N. Sarvamangala Devi
-
Publication number: 20030096400Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel chemically modified G-CSF compositions and related methods of preparation.Type: ApplicationFiled: October 4, 2002Publication date: May 22, 2003Applicant: Amgen, Inc.Inventor: Olaf B. Kinstler
-
Publication number: 20030082667Abstract: The invention concerns a novel chromogenic substrate based on Alizarin. The invention also concerns the uses to which this substrate can be put, and a formulation containing such a substrate.Type: ApplicationFiled: June 3, 2002Publication date: May 1, 2003Inventors: Lyle Armstrong, Arthur James
-
Publication number: 20030069400Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.Type: ApplicationFiled: April 1, 2002Publication date: April 10, 2003Applicant: Xenova Research LimitedInventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers, Malcolm L. Gefter
-
Patent number: 6528485Abstract: Described are various human growth hormone releasing factor-PEG conjugates as well as their pharmaceutical use.Type: GrantFiled: June 5, 2000Date of Patent: March 4, 2003Assignee: Applied Research Systems ARS Holding N.V.Inventors: Francesco Maria Veronese, Paolo Caliceti, Oddone Schiavon
-
Publication number: 20030008818Abstract: The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent.Type: ApplicationFiled: December 19, 2001Publication date: January 9, 2003Applicant: California Institute of Technology and Insert Therapeutics, IncInventors: Suzie Hwang Pun, Hector Gonzalez, Mark E. Davis, Nathalie Bellocq, Jianjun Cheng
-
Patent number: 6461876Abstract: The present invention provides novel 1,2-dioxetanes derived from spiro-fused ketones with or without &pgr;-electrons in the ring or with carbon-carbon double bond(s) in the spiro-fused ring. Additionally, these new dioxetanes have electron donating or withdrawing groups at the four-membered peroxide ring to render these dioxetanes active at all sites.Type: GrantFiled: August 21, 2000Date of Patent: October 8, 2002Inventor: Brij P. Giri
-
Patent number: 6429297Abstract: The present invention relates to a compound of the formula These modified streptavidin compounds have are useful as part of a delivery system to deliver a molecule to a target site for use in diagnosis or therapy.Type: GrantFiled: February 3, 2000Date of Patent: August 6, 2002Assignee: University of RochesterInventor: Scott F. Rosebrough
-
Publication number: 20020082400Abstract: Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide duplexes of at least 20 base pairs that have significant binding activity-for human lupus anti-dsDNA autoantibodies.Type: ApplicationFiled: December 29, 2000Publication date: June 27, 2002Inventors: Stephen M. Coutts, David S. Jones, Douglas Alan Livingston, Lin Yu
-
Patent number: 6383766Abstract: The present invention relates to compositions comprising novel reduced cortisol conjugates, methods for their preparation and use in immunoassays for cortisol. In another aspect, it relates to conjugates of reduced cortisol as immunogens or haptens for eliciting anti-cortisol or anti-reduced cortisol antibodies.Type: GrantFiled: September 30, 1999Date of Patent: May 7, 2002Assignee: Ortho-Clinical Diagnostics, Inc.Inventors: Harold C. Warren, Brian A. Snyder, Lisa D. Sprague, Shirley Y. Lynn, Paul B. Contestable, Holly L. Groth
-
Publication number: 20020052443Abstract: Branched, substantially non-antigenic polymers are disclosed. Conjugates prepared with the polymers and biologically active molecules such as proteins and peptides demonstrate extended circulating life in vivo. Substantially fewer sites on the biologically active material are used as attachment sites. Methods of forming the polymer, conjugating the polymers with biologically active moieties and methods of using the conjugates are also disclosed.Type: ApplicationFiled: April 7, 2000Publication date: May 2, 2002Inventors: Richard B Greenwald, Anthony J Martinez
-
Publication number: 20020032316Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.Type: ApplicationFiled: June 14, 2001Publication date: March 14, 2002Applicant: Cantab Pharmaceuticals Research LimitedInventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers, Malcolm L. Gefter
-
Patent number: 6333164Abstract: There can be provided a fungal antigen which is an insoluble fraction obtainable from fungal cells of which cell wall has been substantially removed or at least partially removed; a process for producing the same; a nucleic acid encoding the fungal antigen; a biologic product containing the fungal antigen; a method of stimulating immunological responses by using the biologic product; a method of suppressing allergic reaction to fungi in a vertebrate; and a method for diagnosing a disease caused by fungi in a vertebrate.Type: GrantFiled: March 4, 1999Date of Patent: December 25, 2001Assignee: Takara Shuzo Co., Ltd.Inventors: Kazutoh Takesako, Shigetoshi Mizutani, Masahiro Endo, Ikunoshin Kato
-
Patent number: 6309633Abstract: The invention provides a drug-oligomer conjugate having the following general formula: wherein D is a therapeutic drug moiety; H and H′ are each a hydrophilic moiety, independently selected from the group consisting of straight or branched PEG polymers having from 2 to 130 PEG subunits, and sugars; L is a lipophilic moiety selected from the group consisting of alkyl groups having 2-26 carbon atoms, cholesterol, adamantane and fatty acids; o is a number from 1 to the maximum number of covalent bonding sites on H; m+n+p together have a value of at least one and not exceeding the total number of covalent bonding sites on D for the —H′, —L and —H—L substituents; the H—L bond(s) are hydrolyzable and the D—L′ bond(s), when present, are hydrolyzable; the conjugate being further characterized by one of the following: (i) m is 0 and p is at least 1; (ii) n is 0 and p is at least 1; (iii) m and n are each 0 and p is at least 1; (iv) p isType: GrantFiled: June 19, 1999Date of Patent: October 30, 2001Assignee: Nobex CorporationInventors: Nnochiri Ekwuribe, Muthukumar Ramaswamy, Jayanthi Sethuraman Rajagopalan
-
Patent number: 6299881Abstract: A method for producing a conjugate vaccine includes mixing a uronium salt reagent with a first moiety (e.g., a polysaccharide). According to the invention, the uronium salt reagent has a chemical structure corresponding to formula I: wherein R1 is defined as wherein R6 represents the carbon, hydrogen, and optionally one or more heteroatoms which, together with the nitrogen atom to which they are attached, constitute a 5 to 10 membered heterocyclic ring, which may be substituted or unsubstituted. R2, R3, R4, and R5, each independently represents a hydrogen atom, a substituted or unsubstituted alkyl having 1 to 6 carbon atoms, a substituted or unsubstituted alkenyl having 2 to 6 carbon atoms, or an alkynyl having 2 to 6 carbon atoms. Alternatively, R2 and R3, when taken together, can represent the carbon, hydrogen, sulfur, nitrogen, or oxygen atoms necessary to complete a 5 to 7 membered heterocyclic ring with the nitrogen atom to which they are attached.Type: GrantFiled: March 23, 1998Date of Patent: October 9, 2001Assignee: Henry M. Jackson Foundation for the Advancement of Military MedicineInventors: Andrew Lees, James J. Mond
-
Patent number: 6277984Abstract: Fluorescent monomethine cyanine complexes rigidized a two-carbon alkyl group between the nitrogen's of the cyanine's heterocycles are provided and having the structure wherein R1 through R7 represent various selected groups or ring structures that may be chosen to provide desired solubility, reactive, or spectral properties.Type: GrantFiled: February 11, 1999Date of Patent: August 21, 2001Assignee: Carnegie Mellon UniversityInventors: Ratnakar B. Mujumdar, Alan S. Waggoner, Bhalchandra M. Karandikar
-
Patent number: 6252087Abstract: Nitroaromatic compounds and immunogenic conjugates comprising a novel nitroaromatic compound and a carrier protein are disclosed. The invention further presents monoclonal antibodies highly specific for the claimed nitroaromatic compounds, the compounds' protein conjugates, the compounds' reductive byproducts, and adducts formed between the compounds and mammalian hypoxic cell tissue proteins. The invention is further directed to methods for detecting tissue hypoxia using immunohistological techniques, non-invasive nuclear medicinal methods, or nuclear magnetic resonance. Diagnostic kits useful in practicing the methods of claimed invention are also provided.Type: GrantFiled: July 28, 1998Date of Patent: June 26, 2001Assignee: The Trustees of the University of PennsylvaniaInventors: Cameron J. Koch, Alexander V. Kachur, Sydney M. Evans, Chyng-Yann Shiue, Ian R. Baird, Kirsten A. Skov, William R. Dolbier, Jr., An-Rong Li, Brian R. James
-
Patent number: 6248334Abstract: A process for preparing a protein-polysaccharide conjugate includes reacting a protein with a polysaccharide to produce a mixture including a protein-polysaccharide conjugate and free protein. At least one unreacted reagent or low molecular weight component is removed from this mixture, without removing all of the free protein, to provide a purified mixture that contains the protein-polysaccharide conjugate and free protein. This purified mixture can be used as a conjugate vaccine, immunogen, or immunological reagent. Keeping the free protein in the purified mixture with the conjugate saves time and money in the conjugate production process. In another aspect of the invention, the purified mixture of the protein-polysaccharide conjugate and free protein is reacted with a hapten to produce a conjugate mixture including a hapten-protein conjugate and a hapten-protein-polysaccharide conjugate.Type: GrantFiled: January 6, 1998Date of Patent: June 19, 2001Assignee: Henry M. Jackson Foundation for the Advancement of Military MedicineInventors: Andrew Lees, James Mond
-
Patent number: 6225073Abstract: The present invention provides antibodies useful in assays for mycophenolic acid (MPA). These antibodies bind MPA and are able to distinguish MPA from its esters, such as morpholinoethyl E-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate, and/or its metabolites, such as mycophenolic acid glucuronide. The present invention also provides conjugates of labels and MPA or MPA analogs. The antibodies of the invention are capable of binding these conjugates and are also capable of inhibiting the activity of the label when bound to the conjugates. The present invention also provides methods for the determination of MPA in a sample suspected of containing MPA that use the antibodies and/or conjugates of the invention. The present invention also provides assay reagents as well as packaged kits useful for performing the methods of the invention.Type: GrantFiled: July 7, 1994Date of Patent: May 1, 2001Assignee: Dade Behring Marburg GmbHInventors: Svetlana Alexander, Dariush Davalian
-
Patent number: 6217873Abstract: Provided by this invention are essentially homogeneous, defined compositions of matter and hetero-polyoximes of defined structure comprising a baseplate structure having a plurality of oxime bonds, wherein each oxime bond links a specifically active molecule to the baseplate. Also provided are novel baseplates having a plurality of oxime forming complementary reactive groups and novel specifically reactive molecules having an oxime forming complementary reactive group. Also provided by this invention are methods of preparing these novel compositions of matter by chemoselectively ligating via oxime bond formation a complementary orthogonal reactive group on the baseplate to a complementary reactive orthogonal group on a specifically active molecule. Methods of using these defined compositions of matter as well as pharmaceutical compositions comprising these defined compositions of matter and methods of their use are also provided by this invention.Type: GrantFiled: January 5, 1996Date of Patent: April 17, 2001Assignee: Gryphon SciencesInventors: Keith Rose, Robin E. Offord
-
Patent number: 6174530Abstract: Provided by this invention are essentially homogeneous, defined compositions of matter comprising a baseplate structure having a plurality of oxime bonds, wherein each oxime bond links a specifically active molecule to the baseplate. Also provided are novel baseplates having a plurality of oxime forming complementary reactive groups and novel specifically reactive molecules having an oxime forming complementary reactive group. Also provided by this invention are methods of preparing these novel compositions of matter by chemoselectively ligating via oxime bond formation a complementary orthogonal reactive group on the baseplate to a complementary reactive orthogonal group on a specifically active molecule. Methods of using these defined compositions of matter as well as pharmaceutical compositions comprising these defined compositions of matter and methods of their use are also provided by this invention.Type: GrantFiled: August 31, 1993Date of Patent: January 16, 2001Assignee: Gryphon SciencesInventors: Keith Rose, Robin Ewart Offord
-
Patent number: 6172202Abstract: A process for the preparation of a conjugate between a poly (ethylene glycol) and a protein or glycoprotein, the process comprising specifically binding the domain to a specific binder, to shield the domain from the poly (ethylene glycol) in the following conjugating step, thereafter conjugating the poly (ethylene glycol) to the protein or glycoprotein, wherein conjugation of the poly (ethylene glycol) to the domain is avoided and thereafter releasing the specific binder from the domain without releasing the poly (ethylene glycol) from the protein or glycoprotein, wherein the protein or glycoprotein is other than a proteolytic enzyme selected from the group consisting of trypsin, urokinase, tissue plasminogen activator, plasmin, chymotrypsin, elastase and kallikrein.Type: GrantFiled: July 7, 1997Date of Patent: January 9, 2001Assignee: Pharmacia S.p.A.Inventors: Fabrizio Marcucci, Ruth Gregory
-
Patent number: 6160098Abstract: The present invention relates to cross-linked hemoglobins, and particularly to methods of controlling the functionality of such hemoglobins. The controlled functionalities include the P.sub.50 and the Hill coefficient. The present invention provides methods for producing a cross-linked hemoglobin with specific final functionalities by regulating the amount of both total hemoglobin and R-state hemoglobin prior to cross-linking, and by modulating cross-linking reaction conditions such as time, temperature, pH and the ratio of cross-linking reagent to hemoglobin.Type: GrantFiled: May 29, 1998Date of Patent: December 12, 2000Assignee: Baxter Biotech Technology SarlInventor: Bruce A. Kerwin
-
Patent number: 6136606Abstract: The invention provides a vaccine composition in the form of a kit, comprising a first container containing an antigenic preparation comprising influenza antigen or antigens; and a second container containing an effective adjuvant amount of a chitosan which is a deacetylated chitin which is at least 80% deacetylated. The antigenic preparation in the first container preferably comprises haemagglutinin and neuraminidase influenza antigens.Type: GrantFiled: April 29, 1998Date of Patent: October 24, 2000Assignee: Medeva Holdings BVInventor: Steven Neville Chatfield
-
Patent number: 6120777Abstract: The present invention relates to a malondialdehyde-acetaldehyde adduct which acts as a specific immune-enhancing factor. In addition to its highly specific and immunogenic properties, the factor is highly fluorescent. It has an excitation frequency of about 398 nanometers and an absorbance of about 460 nanometers. The factor is also highly reactive and is also adducted to antigens including complex proteins, lipids, carbohydrates or DNA.Type: GrantFiled: May 27, 1997Date of Patent: September 19, 2000Assignee: The Board of Regents of the University of NebraskaInventors: Geoffrey M. Thiele, Thomas L. McDonald, Dean J. Tuma, Lynell W. Klassen, Michael F. Sorrell
-
Patent number: 6037455Abstract: The present invention is directed to novel propoxyphene derivatives which are synthesized for the covalent attachment to antigens (proteins or polypeptides) for the preparation of antibodies or receptors to propoxyphene and propoxyphene metabolites. The resulting novel antigens may be used for the production of antibodies or receptors using standard methods. Once generated, the antibodies or receptors and the novel derivatives which are covalently attached to proteins, polypeptides or labels may be used in the immunoassay process.Type: GrantFiled: November 9, 1992Date of Patent: March 14, 2000Assignee: Biosite Diagnostics IncorporatedInventor: Kenneth F. Buechler
-
Patent number: 6037452Abstract: Factor VIIIC:vWF, Factor VIII C, Factor IX or Factor IX or the activated co-factors thereof are covalently linked to a poly(alkylene oxide).Type: GrantFiled: April 10, 1992Date of Patent: March 14, 2000Assignee: Alpha Therapeutic CorporationInventors: Hitoshi Minamino, Edward H. Mealey
-
Patent number: 6025324Abstract: Polyethylene and polypropylene protein conjugates which modulate body weight of ani is and humans for the treatment, prevention and control obesity and associated diseases or conditions, and the recombinant expression of these biologically active proteins in purified and homogeneous forms.Type: GrantFiled: May 15, 1996Date of Patent: February 15, 2000Assignee: Hoffmann-La Roche Inc.Inventors: Pascal Sebastian Bailon, Arthur Campfield, Rene Devos, Yves Guisez
-
Patent number: 6025325Abstract: Polyethylene and polypropylene protein conjugates which modulate body weight of animals and humans for the treatment, prevention and control of obesity and associated diseases or conditions, and the recombinant expression of these biologically active proteins in purified and homogeneous forms.Type: GrantFiled: May 15, 1996Date of Patent: February 15, 2000Assignee: Hoffman-La Roche Inc.Inventors: Arthur Campfield, Rene Devos, Yves Guisez